[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626747":3},{"organization":4,"outcomesModule":7,"designInfo":58,"detailedDescription":57,"studyPopulation":57,"armGroups":64,"interventions":81,"overallOfficials":57,"centralContacts":95,"locations":101,"responsibleParty":135,"collaborators":57,"id":137,"slug":57,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":57,"eligibilityCriteria":142,"healthyVolunteers":138,"sex":143,"minAge":144,"maxAge":57,"enrollmentInfo":145,"targetDuration":57,"studyType":148,"phases":149,"briefSummary":152,"conditions":153,"keywords":57,"overallStatus":104,"whyStopped":57,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},{"fullName":5,"class":6},"TORL Biotherapeutics, LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":57},[9,13,16,18,22],{"measure":10,"description":11,"timeFrame":12},"Evaluate the safety of TORL-5-700 as a monotherapy","Assessment of adverse events according to NCI-CTCAE Version 5.0","though study completion, an average of 2.5 years",{"measure":14,"description":15,"timeFrame":12},"Assess the antitumor activity of TORL-5-700 as monotherapy","Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria",{"measure":17,"description":11,"timeFrame":12},"Evaluate the safety of TORL-5-700 in combination with other agents",{"measure":19,"description":20,"timeFrame":21},"Determine the Maximum Tolerated Dose (MTD)","Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)","21 days from the start of treatment",{"measure":23,"description":24,"timeFrame":21},"Determine the Recommended Phase 2 Dose (RP2D)","Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities",[26,30,32,34,36,38,40,42,44,47,49,52,54],{"measure":27,"description":28,"timeFrame":29},"Maximum Serum Concentration of TORL-5-700 (Cmax)","Pk assessment","though end of study treatment, an average of 5 months",{"measure":31,"description":28,"timeFrame":29},"Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents",{"measure":33,"description":28,"timeFrame":29},"Terminal Half-life (t1\u002F2) of Serum TORL-5-700",{"measure":35,"description":28,"timeFrame":29},"Terminal Half-life (t1\u002F2) of Serum TORL-5-700 in combination with other agents",{"measure":37,"description":28,"timeFrame":29},"Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration",{"measure":39,"description":28,"timeFrame":29},"Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents",{"measure":41,"description":28,"timeFrame":29},"Clearance (CL) of TORL-5-700",{"measure":43,"description":28,"timeFrame":29},"Clearance (CL) of TORL-5-700 in combination with other agents",{"measure":45,"description":46,"timeFrame":29},"Volume of distribution of TORL-5-700","PK assessment",{"measure":48,"description":46,"timeFrame":29},"Volume of distribution of TORL-5-700 in combination with other agents",{"measure":50,"description":51,"timeFrame":29},"Immunogenicity of TORL-5-700","Immunogenicity will be measured by incidence of treatment emergent ADAs",{"measure":53,"description":51,"timeFrame":29},"Immunogenicity of TORL-5-700 in combination with other agents",{"measure":55,"description":56,"timeFrame":12},"Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents","Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria",null,{"allocation":59,"interventionModel":60,"interventionModelDescription":57,"primaryPurpose":61,"observationalModel":57,"timePerspective":57,"maskingInfo":62},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":63,"maskingDescription":57,"whoMasked":57},"NONE",[65,71,76],{"label":66,"type":67,"description":68,"interventionNames":69},"Part 1: Monotherapy Dose Escalation","EXPERIMENTAL","TORL-5-700 Administered once every three weeks",[70],"Drug: TORL-5-700",{"label":72,"type":67,"description":73,"interventionNames":74},"Part 2: Monotherapy Expansion","TORL-5-700 at MTD\u002FRP2D Administered once every three weeks",[75],"Drug: TORL-5-700 at MTD\u002FRP2D",{"label":77,"type":67,"description":78,"interventionNames":79},"Part 3: Combination Evaluation","TORL-5-700 at MTD\u002FRP2D Administered once every three weeks in combination with another agent",[80],"Drug: TORL-5-700 at MTD\u002FRP2D in combination with another agent",[82,87,91],{"type":83,"name":84,"description":85,"armGroupLabels":86,"otherNames":57},"DRUG","TORL-5-700","Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks",[66],{"type":83,"name":88,"description":89,"armGroupLabels":90,"otherNames":57},"TORL-5-700 at MTD\u002FRP2D","Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)\u002FRecommended Phase 2 Dose (RP2D) Administered once every three weeks",[72],{"type":83,"name":92,"description":93,"armGroupLabels":94,"otherNames":57},"TORL-5-700 at MTD\u002FRP2D in combination with another agent","Part 3: Combination Evaluation - TORL-5-700 at MTD\u002FRP2D administered every three weeks in combination with another agent",[77],[96],{"name":97,"role":98,"phone":99,"phoneExt":57,"email":100},"Timothy Welliver, M.D.","CONTACT","(310) 598-5969","timothy.welliver@torlbio.com",[102,116,125],{"facility":103,"status":104,"city":105,"state":106,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":115,"contacts":57},"UCLA","RECRUITING","Santa Monica","California","90404","United States","US",{"type":111,"coordinates":112},"Point",[113,114],-118.49138,34.01949,{"lat":114,"lon":113},{"facility":117,"status":104,"city":118,"state":106,"zip":119,"country":108,"countryCode":109,"cosmosGeoPoint":120,"geoPoint":124,"contacts":57},"Stanford University","Stanford","94305",{"type":111,"coordinates":121},[122,123],-122.16608,37.42411,{"lat":123,"lon":122},{"facility":126,"status":104,"city":127,"state":128,"zip":129,"country":108,"countryCode":109,"cosmosGeoPoint":130,"geoPoint":134,"contacts":57},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":111,"coordinates":131},[132,133],-86.78444,36.16589,{"lat":133,"lon":132},{"type":136,"investigatorFullName":57,"investigatorTitle":57,"investigatorAffiliation":57,"oldNameTitle":57,"oldOrganization":57},"SPONSOR","100626747",false,"NCT07439653","A Study of TORL-5-700 in Relapsed\u002FRefractory Non Hodgkin's Lymphoma","A Phase 1\u002F2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* At least 1 measurable lesion per Lugano criteria.\n* Tumor tissue is available.\n* Adequate organ function\n\nExclusion Criteria:\n\n* T-cell lymphoma\n* CLL or SL\n* Burkitt lymphoma and high-grade B-cell lymphoma\n* CNS involvement\n* Peripheral neuropathy \\> Grade 2\n* Uncontrolled medical conditions\n* Viral infections","ALL","18 Years",{"count":146,"type":147},155,"ESTIMATED","INTERVENTIONAL",[150,151],"PHASE1","PHASE2","A Phase 1\u002F2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R\u002FR NHL",[154],"Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","2026-06-09",{"date":157,"type":158},"2026-06-11","ACTUAL",{"date":160,"type":158},"2026-03-31",{"date":162,"type":147},"2029-09-30",{"name":5,"class":6},3]